| Not Yet Recruiting | Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities NCT06997198 | University Hospitals Cleveland Medical Center | Phase 4 |
| Not Yet Recruiting | Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia NCT07365462 | Neurocrine Biosciences | Phase 2 |
| Recruiting | Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise NCT07173920 | Peking University Sixth Hospital | N/A |
| Recruiting | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Re NCT07105111 | Neurocrine Biosciences | Phase 4 |
| Not Yet Recruiting | Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients NCT06218719 | Power Life Sciences Inc. | — |
| Withdrawn | Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities NCT06107829 | Stephen Ruedrich | Phase 4 |
| Withdrawn | Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine NCT05053321 | Yale University | Phase 1 |
| Completed | Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets NCT06474650 | Luye Pharma Group Ltd. | Phase 1 |
| Completed | Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects NCT06216054 | Luye Pharma Group Ltd. | Phase 1 |
| Unknown | Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes NCT06011408 | iRxReminder | N/A |
| Completed | Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tar NCT05859698 | Neurocrine Biosciences | Phase 4 |
| Completed | A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subj NCT05238701 | Luye Pharma Group Ltd. | Phase 1 |
| Recruiting | Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates NCT03495024 | Corporal Michael J. Crescenz VA Medical Center | Phase 4 |
| Completed | Pimavanserin Treatment in TS NCT04794413 | Joseph Jankovic | EARLY_Phase 1 |
| Completed | Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia NCT03287778 | University of North Carolina, Chapel Hill | N/A |
| Withdrawn | Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia NCT03254186 | Emory University | Phase 2 / Phase 3 |
| Completed | Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia NCT03497013 | Suzhou Psychiatric Hospital | N/A |
| Completed | Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia NCT03176771 | Tanabe Pharma Corporation | Phase 2 / Phase 3 |
| Unknown | Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents NCT03062033 | Neurocrine Biosciences | — |
| Unknown | Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia. NCT02840760 | Shanghai Mental Health Center | N/A |
| Completed | Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia NCT02736955 | Neurocrine Biosciences | Phase 3 |
| Terminated | Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia NCT02524886 | GGZ Centraal | N/A |
| Active Not Recruiting | ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders NCT02252380 | InSightec | N/A |
| Completed | Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia NCT02405091 | Neurocrine Biosciences | Phase 3 |
| Completed | Addressing Involuntary Movements in Tardive Dyskinesia NCT02291861 | Auspex Pharmaceuticals, Inc. | Phase 3 |
| Completed | Reducing Involuntary Movements in Participants With Tardive Dyskinesia NCT02198794 | Auspex Pharmaceuticals, Inc. | Phase 3 |
| Completed | A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia NCT02274558 | Neurocrine Biosciences | Phase 3 |
| Completed | Aim to Reduce Movements in Tardive Dyskinesia NCT02195700 | Auspex Pharmaceuticals, Inc. | Phase 2 / Phase 3 |
| Unknown | D-Serine Treatment For Tardive Dyskinesia NCT01804920 | Herzog Hospital | N/A |
| Completed | NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia NCT01733121 | Neurocrine Biosciences | Phase 2 |
| Completed | NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder ( NCT01688037 | Neurocrine Biosciences | Phase 2 |
| Completed | Xenazine in Late Dyskinetic Syndrome With Neuroleptics NCT01543321 | Centre Hospitalier Universitaire, Amiens | Phase 3 |
| Completed | The Assessment of Movement Disorders Utilizing Live Two-Way Video NCT01467089 | Northwell Health | — |
| Completed | NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder NCT01393600 | Neurocrine Biosciences | Phase 2 |
| Withdrawn | Pyridoxal Kinase Activity in Tardive Dyskinesia NCT01908452 | Beersheva Mental Health Center | Phase 3 |
| Completed | Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia NCT01267188 | Neurocrine Biosciences | Phase 2 |
| Terminated | Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia NCT00917293 | Medicure | Phase 2 |
| Completed | Melatonin Treatment for Tardive Dyskinesia in Schizophrenia NCT01391390 | Beijing HuiLongGuan Hospital | N/A |
| Unknown | Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia NCT00621634 | Université de Montréal | Phase 2 |
| Completed | Extract of Ginkgo Biloba and Tardive Dyskinesia NCT00672373 | Beijing HuiLongGuan Hospital | Phase 3 |
| Completed | Piracetam for Treatment Tardive Dyskinesia NCT00190008 | Beersheva Mental Health Center | Phase 3 |
| Completed | Tardive Dyskinesia and Cognitive Function NCT00926965 | Taipei Veterans General Hospital, Taiwan | Phase 4 |
| Completed | Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia NCT00401089 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 1 / Phase 2 |
| Completed | Treatment of Tardive Dyskinesia With Galantamine NCT00164242 | Caroff, Stanley N., M.D. | Phase 4 |
| Completed | Levetiracetam Treatment of Tardive Dyskinesia NCT00291213 | Yale University | Phase 3 |